Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study

Lasorella, Stefania; Porto, Rossella; Iezzi, Maria Laura; Pistone, Carmelo; Marseglia, Gian Luigi; Verrotti, Alberto; Brambilla, Ilaria

doi:10.1080/09513590.2019.1655726

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both formulations show similar efficacy and safety profiles. 16) Our study aimed to investigate the long-term therapeutic efficacy of CPP treatment using triptorelin pamoate (TP) 3-month depot in female patients and to compare its effects with that of triptorelin acetate (TA) 1-month depot.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty

Park,

Gwag,

Kim

et al. 2024

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHa) are expected to achieve better compliance in patients with central precocious puberty (CPP). However, 1month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment. Methods:In this retrospective study, 69 Korean girls with CPP were prescribed with either triptorelin pamoate (TP) 3-month depot (n = 29) or triptorelin acetate (TA) 1-month depot (n = 40) and were followed up for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics of the subjects were similar between the two groups. In the TP 3-month depot group, 27/29 (93.1 %) of patients exhibited suppressed LH levels (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8 ± 0.4 years at the start of treatment to 0.6 ± 0.5 years at 1 year post-treatment. The gain in predicted adult height (PAH) at 1 year after the end of treatment was similar between the TP 3month and TA 1-month depot groups (5.2 ± 3.1 and 5.3 ± 2.4 cm, respectively; P = 0.875). Conclusion:The 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For the patients' convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Although the acetate salt was the first to be developed, the pamoate salt is commonly used in slowrelease formulations of pharmaceutical agents. The formulations show similar efficacy and safety profiles [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty

Park,

Gwag,

Kim

et al. 2024

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Treg cells can also express programmed cell death protein 1 (PD-1) to influence the polarization of macrophages/microglia. The major of research indicates that the PD-1/PD-L1 signalling pathway sustains or promotes Treg cell expansion, Foxp3 expression, and immunosuppressive function [ 24 – 26 ]. PD-1 inhibits the polarization of macrophages/microglia towards the pro-inflammatory type post-SCI [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

Role of regulatory T cells in spinal cord injury

et al. 2023

View full text Add to dashboard Cite

Spinal cord injury is an intricate process involving a series of multi-temporal and multi-component pathological events, among which inflammatory response is the core. Thus, it is crucial to find a way to prevent the damaging effects of the inflammatory response. The research has found that Treg cells can suppress the activation, proliferation, and effector functions of many parenchymal cells by multiple mechanisms. This review discusses how Treg cells regulate the inflammatory cells to promote spinal cord recovery. These parenchymal cells include macrophages/microglia, oligodendrocytes, astrocytes, and others. In addition, we discuss the adverse role of Treg cells, the status of treatment, and the prospects of cell-based therapies after spinal cord injury. In conclusion, this review provides an overview of the regulatory role of Treg cells in spinal cord injury. We hope to offer new insights into the treatment of spinal cord injury.

show abstract

Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts

Bharate

2021

Pharm Res

View full text Add to dashboard Cite

Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study

Cited by 7 publications

References 20 publications

Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty

Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty

Role of regulatory T cells in spinal cord injury

Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts

Contact Info

Product

Resources

About